Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131 I-MIBG for Refractory Neuroblastoma
NCT00293319Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, sponsored by University of California, San Francisco. Primary endpoints: Ability of iodine I 131 metaiodobenzylguanidine to provide palliative therapy and Acute and late toxicities. Started Apr 2005; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00293319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293319.